Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients

Wang,Xiaobin; Wang,Huihan; Song,Yongsheng

doi:10.3892/ol.2018.9617

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients

Authors:
- Xiaobin Wang
- Huihan Wang
- Yongsheng Song
View Affiliations

Affiliations: Department of Urinary Surgery (II), Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Hematology (II), Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: October 24, 2018 https://doi.org/10.3892/ol.2018.9617
Pages: 201-208

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical efficacy and mechanism of Pralatrexate (PTX) combined with Palbociclib Isethionate (PAL) in the treatment of bladder cancer patients was investigated. A retrospective analysis of medical records of 82 bladder cancer patients admitted to Shengjing Hospital of China Medical University from February 2015 to February 2018 was performed. Patients treated with PTX combined with PAL served as study group (42 cases) and patients with conventional GC (gemcitabine plus cisplatin) chemotherapy regimen were the control group (40 cases). Changes in liver function indexes before and after treatment were observed, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBil). RT-qPCR was used for detection of relative expression levels of serum dihydrofolate reductase (DHFR) and vascular endothelial growth factor (VEGF) before and after treatment in the two groups. The clinical efficacy after treatment and adverse reactions during treatment were observed in the two groups. There was no significant difference in the clinical remission rate (RR) nor in the serum ALT, AST, ALP and TBil levels between the study and the control groups (P>0.05). Concentrations of serum ALT, AST, ALP and TBil were significantly higher than those before treatment in both groups (P<0.05). Serum ALT, AST, ALP and TBil concentrations in study group were significantly lower than those in control group (P<0.05). There was no significant difference in the incidence of thrombocytopenia and leukopenia between the two groups (P>0.05). There was no significant difference in relative expression levels of serum DHFR mRNA and VEGF mRNA before treatment between the study and control groups (P>0.05). Those after treatment were significantly lower than those before treatment in both groups (P<0.05), and those after treatment in study group were significantly lower than those in control group (P<0.05). PTX combined with PAL can reduce adverse reactions of nausea and vomiting and liver function impairment during treatment and suppress tumor neovascularization. This is achieved possibly by inhibiting expression levels of DHFR and VEGF, thereby killing cancer cells. PTX combined with PAL may become a new method for the treatment of bladder cancer patients. DHFR and VEGF are expected to become novel therapeutic targets for the treatment of bladder cancer.

View Figures

View References

1	Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 71:462–475. 2017. View Article : Google Scholar : PubMed/NCBI
2	Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 71:96–108. 2017. View Article : Google Scholar : PubMed/NCBI
3	Arcangeli G, Strigari L and Arcangeli S: Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Crit Rev Oncol Hematol. 95:387–396. 2015. View Article : Google Scholar : PubMed/NCBI
4	Tekin A, Aki FT and Ozen H: Radical cystectomy versus alternative treatments for muscle-confined bladder cancer. Int Urol Nephrol. 33:357–362. 2001. View Article : Google Scholar : PubMed/NCBI
5	Kim HS, Jeong CW, Kwak C, Kim HH and Ku JH: Adjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and network meta-analysis of randomized clinical trials. Oncotarget. 8:81204–81214. 2017.PubMed/NCBI
6	Tanino R, Tsubata Y, Harashima N, Harada M and Isobe T: Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. Oncotarget. 9:16807–16821. 2018. View Article : Google Scholar : PubMed/NCBI
7	Bhushan B, Ahuja D, Verma S, Saluja S, Siddiqui S and Kapur S: Relation of cell viability and apoptosis with clinical remission following induction chemotherapy in ALL and AML. J Exp Clin Cancer Res. 26:313–321. 2007.PubMed/NCBI
8	Depau L, Brunetti J, Falciani C, Scali S, Riolo G, Mandarini E, Pini A and Bracci L: Coupling to a cancer-selective heparan-sulfate-targeted branched peptide can by-pass breast cancer cell resistance to methotrexate. Oncotarget. 8:76141–76152. 2017. View Article : Google Scholar : PubMed/NCBI
9	Marchi E, Mangone M, Zullo K and O'Connor OA: Pralatrexate pharmacology and clinical development. Clin Cancer Res. 19:6657–6661. 2013. View Article : Google Scholar : PubMed/NCBI
10	Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, et al: Specific antileukemic activity of PD0332991, a CDK4/6 inhibitor, against Philadelphia chromosome-positive lymphoid leukemia. Mol Cancer Ther. 15:94–105. 2016. View Article : Google Scholar : PubMed/NCBI
11	Fawal MA, Jungas T, Kischel A, Audouard C, Iacovoni JS and Davy A: Cross talk between one-carbon metabolism, Eph signaling, and histone methylation promotes neural stem cell differentiation. Cell Rep. 23:2864–2873.e7. 2018. View Article : Google Scholar : PubMed/NCBI
12	Raghunathachar Sahana K, Akila P, Prashant V, Sharath Chandra B and Nataraj Suma M: Quantitation of vascular endothelial growth factor and interleukin-6 in different stages of breast cancer. Rep Biochem Mol Biol. 6:33–39. 2017.PubMed/NCBI
13	Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, et al: Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 196:1021–1029. 2016. View Article : Google Scholar : PubMed/NCBI
14	Mazza P, Moran GW, Li G, Robins DJ, Matulay JT, Herr HW, Decastro GJ, McKiernan JM and Anderson CB: Conservative management following clinical complete response to neoadjuvant chemotherapy of muscle invasive bladder cancer: Contemporary outcomes of a multi-institutional cohort study. J Urol. May 19–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
15	Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez J, Sadhasivam S, Klein TE, et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 102:213–218. 2017. View Article : Google Scholar : PubMed/NCBI
16	Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al; OAK Study Group, . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
17	Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, et al: Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 1:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
18	Perkins JR, Dawes JM, McMahon SB, Bennett DL, Orengo C and and Kohl M: ReadqPCR and NormqPCR: R packages for the reading, quality checking and normalisation of RT-qPCR quantification cycle (Cq) data. BMC Genomics. 13:2962012. View Article : Google Scholar : PubMed/NCBI
19	Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM and Zietman AL: Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 32:3801–3809. 2014. View Article : Google Scholar : PubMed/NCBI
20	Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, Engel O, Fisch M, Pantel K and Rink M: A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int J Cancer. 140:381–389. 2017. View Article : Google Scholar : PubMed/NCBI
21	Qi X, Wong BL, Lau SH, Ng KT, Kwok SY, Kin-Wai Sun C, Tzang FC, Shao Y, Li CX, Geng W, et al: A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma. Oncotarget. 8:85311–85325. 2017. View Article : Google Scholar : PubMed/NCBI
22	Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz SB and Vaughn DJ: Cisplatin, gemcitabine, and lapatinib as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer Res Treat. 48:1084–1091. 2016. View Article : Google Scholar : PubMed/NCBI
23	Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, Massidda B, Rubagotti A, Giannarelli D and Boccardo F; Study Group, . Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: An Italian, multicenter, randomized phase III trial. Ann Oncol. 23:695–700. 2012. View Article : Google Scholar : PubMed/NCBI
24	Cipolleschi MG, Marzi I, Rovida E, Olivotto M and Dello Sbarba P: Low-dose methotrexate enhances cycling of highly anaplastic cancer cells. Cell Cycle. 16:280–285. 2017. View Article : Google Scholar : PubMed/NCBI
25	Gupta SC, Sung B, Prasad S, Webb LJ and Aggarwal BB: Cancer drug discovery by repurposing: Teaching new tricks to old dogs. Trends Pharmacol Sci. 34:508–517. 2013. View Article : Google Scholar : PubMed/NCBI
26	O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Macgregor-Cortelli B, Neylon E, Sarasohn D, Dumetrescu O, et al: Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol. 139:425–428. 2007. View Article : Google Scholar : PubMed/NCBI
27	Hydbring P, Malumbres M and Sicinski P: Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 17:280–292. 2016. View Article : Google Scholar : PubMed/NCBI
28	Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, et al: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 48:2388–2406. 2005. View Article : Google Scholar : PubMed/NCBI
29	Knowles MA and Hurst CD: Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
30	Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J and Nienhuis AW: The functional human dihydrofolate reductase gene. J Biol Chem. 259:3933–3943. 1984.PubMed/NCBI
31	Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 1587:164–173. 2002. View Article : Google Scholar : PubMed/NCBI
32	Li S, Sun W, Wang H, Zuo D, Hua Y and Cai Z: Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338. 2015. View Article : Google Scholar : PubMed/NCBI
33	Poyet C, Thomas L, Benoit TM, Delmo DA, Luberto L, Banzola I, Günthart MS, Sais G, Eberli D, Sulser T, et al: Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. Oncotarget. 8:21871–21883. 2017. View Article : Google Scholar : PubMed/NCBI
34	Hirata S, Matsubara T, Saura R, Tateishi H and Hirohata K: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32:1065–1073. 1989. View Article : Google Scholar : PubMed/NCBI
35	Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, Muschter R, Popken G, König F and Knüchel R: Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol. 174:862–866. 2005. View Article : Google Scholar : PubMed/NCBI